Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer (CROSBI ID 285062)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Ban, Marija ; Petrić Miše, Branka ; Majić, Ana ; Dražić, Ivanka ; Vrdoljak, Eduard
engleski
Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer
Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2- metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. Results: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months ; median overall survival was 11 months. Treatment was well tolerated. Conclusion: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.
breast ; cancer ; heavily pretreated ; HER2- ; hormone receptor positive ; metastatic ; palbociclib
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti